Anti-Inflammatory Properties of Low-Dose Ketamine: Cytokine Modulation

How Low-Dose Ketamine Affects Inflammation

Low-dose ketamine lowers inflammation through several mechanisms, and researchers increasingly treat the anti-inflammatory properties of low-dose ketamine cytokine modulation as a second pathway alongside its role as an NMDA receptor antagonist, the glutamate receptor ketamine blocks to produce its rapid antidepressant and analgesic effects. Sub-anesthetic ketamine also suppresses nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB), a signaling pathway that controls transcription of pro-inflammatory cytokines, and reduces circulating interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) within hours of infusion (De Kock et al., 2013). This combination of glutamatergic and anti-inflammatory activity is central to current research on why ketamine can act faster than conventional antidepressants in patients with an inflammatory depression subtype. For pharmacological background, see the PubChem ketamine compound summary.

Why Inflammation Matters in Depression

Depression research over the past two decades links elevated inflammatory markers to a subset of patients with major depressive disorder. A meta-analysis by Dowlati and colleagues (2010) in Biological Psychiatry found significantly higher serum IL-6 and TNF-alpha in depressed patients versus healthy controls, and later analyses added CRP and IL-1beta to the list (Haapakoski et al., 2015). The relationship runs both directions: interferon-alpha treatment produces depressive symptoms in 30 to 50 percent of hepatitis C patients, timed to peak cytokine induction (Capuron and Miller, 2004), while chronic stress activates inflammatory signaling through the HPA axis (Pace et al., 2006). Brain imaging adds a structural piece: Setiawan and colleagues (2015), in JAMA Psychiatry, used a PET tracer for microglia, the brain's resident immune cells, and found elevated activation in the prefrontal cortex, anterior cingulate cortex, and insula of depressed patients. See the NIMH depression overview for general background.

The Biological Mechanisms Behind Ketamine's Anti-Inflammatory Effect

Ketamine inhibits NF-kappaB activation through several routes, including direct inhibition of IkappaB kinase and interference with Toll-like receptor signaling upstream of the pathway (Sun et al., 2004). In vitro studies using lipopolysaccharide-stimulated macrophages found that clinically relevant ketamine concentrations (1 to 100 microM) significantly reduced NF-kappaB DNA-binding activity and downstream cytokine production, including TNF-alpha, IL-6, and IL-1beta, at concentrations achievable during standard sub-anesthetic IV infusions (Chang et al., 2009).

Reported effects include TNF-alpha reductions of roughly 30 to 70 percent in cell culture and sepsis models (Taniguchi et al., 2001), IL-6 reductions in blood and cerebrospinal fluid (De Kock et al., 2013), IL-1beta attenuation through NF-kappaB inhibition and NLRP3 inflammasome modulation, and possible increases in the anti-inflammatory cytokine IL-10 (Beilin et al., 2004). Ketamine also shifts microglial behavior directly, reducing the transition from resting to activated morphology and suppressing phagocytic activity in stimulated cells (Chang et al., 2009), an effect confirmed in animal models of chronic stress (Wang et al., 2019). Our review of ketamine and neuroinflammation covers this in more depth.

A separate target is the NLRP3 inflammasome, a multiprotein complex that activates caspase-1 and converts pro-IL-1beta and pro-IL-18 into active, secreted forms. Li and colleagues (2019), in the Journal of Neuroinflammation, found that ketamine inhibited NLRP3 assembly in a chronic stress model, lowering hippocampal IL-1beta alongside antidepressant behavioral effects, linked to ketamine's suppression of reactive oxygen species that would otherwise trigger the inflammasome. These findings connect to broader questions about ketamine and immune function.

Clinical Evidence: Surgery and Psychiatric Studies

The strongest clinical evidence for ketamine's anti-inflammatory effect comes from surgical settings. De Kock and colleagues (2013) reviewed perioperative ketamine studies and found consistent reductions in post-surgical CRP and IL-6 among patients receiving sub-anesthetic ketamine versus placebo, with the size of reduction tracking dose and infusion duration. Dale and colleagues (2012), in a randomized, double-blind, placebo-controlled trial in Acta Anaesthesiologica Scandinavica, reported that a ketamine bolus followed by continuous infusion reduced postoperative IL-6 by approximately 40 percent at 24 hours, a pattern replicated across cardiac, abdominal, and orthopedic surgical populations.

In psychiatric research, baseline inflammation appears to modify ketamine's antidepressant response. Kiraly and colleagues (2017), in Psychoneuroendocrinology, found that patients with higher baseline IL-6 showed a greater antidepressant response 24 hours after infusion. Yang and colleagues (2015) and Chen and colleagues (2018) each reported reductions in plasma IL-6 and TNF-alpha after ketamine infusion that correlated with clinical improvement in treatment-resistant depression. These findings have prompted interest in using CRP, particularly above roughly 1 to 3 mg/L, to identify patients most likely to benefit, though this approach still needs prospective validation (Raison and Miller, 2013). Our guide to biomarkers of ketamine response covers this research in more depth.

Relevance to Pain Conditions and Other Anti-Inflammatory Treatments

Chronic pain conditions such as fibromyalgia, complex regional pain syndrome, and neuropathic pain involve neuroinflammatory processes, including microglial activation and spinal cord cytokine elevation that drive central sensitization. Because ketamine blocks NMDA receptors and suppresses neuroinflammation at the same time, researchers propose that its analgesic effect may exceed what either mechanism produces alone (Loix et al., 2011), a pattern supported by perioperative studies showing lower pain scores and lower inflammatory markers in ketamine-treated patients than controls.

Ketamine's anti-inflammatory profile is often compared with established anti-inflammatory antidepressant strategies such as celecoxib, infliximab, and minocycline. A meta-analysis by Kohler-Forsberg and colleagues (2019) in JAMA Psychiatry found a small but significant antidepressant effect from anti-inflammatory agents overall, largest in patients with elevated baseline CRP. Ketamine's anti-inflammatory effect appears comparable to or greater than these agents in available studies, with the added feature of concurrent glutamatergic modulation and faster onset.

What Remains Unclear

Researchers still don't know how much of ketamine's antidepressant effect comes from anti-inflammatory activity versus NMDA-mediated glutamatergic changes, which biomarkers best identify patients likely to benefit from the anti-inflammatory component, and whether combining ketamine with a targeted anti-inflammatory agent could produce an additive effect. Mechanistic studies pairing ketamine with selective cytokine blockade could help separate these contributions. This question matters most for treatment-resistant patients, where neuroinflammation appears most pronounced; see our overview of next steps in treatment-resistant depression for related context.